XIN LI to Humans
This is a "connection" page, showing publications XIN LI has written about Humans.
Connection Strength
0.135
-
Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery. Drug Discov Today. 2024 Jan; 29(1):103832.
Score: 0.024
-
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Eur J Med Chem. 2023 Nov 15; 260:115772.
Score: 0.024
-
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. J Hematol Oncol. 2022 04 08; 15(1):41.
Score: 0.022
-
Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021 04 06; 14(1):56.
Score: 0.020
-
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020 05 13; 13(1):50.
Score: 0.019
-
Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors. Curr Drug Targets. 2013 Jul; 14(8):899-918.
Score: 0.012
-
Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880.
Score: 0.005
-
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167.
Score: 0.004
-
Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 07 30; 39(8):1026-1036.
Score: 0.004